Private equity fund ArchiMed has invested in PlasmidFactory GmbH & Co KG, a German gene and cell therapy specialist. Dr. Martin Schleef, the founder and CEO of PlasmidFactory, will continue to hold a significant stake in the company. Gleiss Lutz advised Dr. Schleef and the other shareholders on the transaction.
PlasmidFactory is a leading contract manufacturer and service provider for plasmid and minicircle DNA. Founded in Bielefeld in 2000, the biopharmaceutical company develops and manufactures high-grade plasmids and minicircles for combating viruses such as COVID-19 and seemingly incurable diseases such as cancer, cystic fibrosis, heart disease, diabetes, haemophilia and AIDS. Plasmids are notably a key component for the production of mRNA COVID-19 vaccines.
With offices in the U.S. and Europe, ArchiMed is a leading private equity fund focused exclusively on the healthcare sector. Its key focuses include biopharmaceutical products and services, life science tools, medical technology, diagnostics, health technologies and software/IT as well as consumer health. In total, ArchiMed manages more than EUR 5 billion across its various funds.
The following team of Gleiss Lutz lawyers, led by Dr. Thomas Menke (partner, M&A, Düsseldorf), advised the shareholders of PlasmidFactory on this transaction: Dr. Fabian Mumme and Kai Zimutta (both M&A, Düsseldorf), Dr. Stefan Mayer (partner), Dr. Leonhard Kornwachs, Dr. Dominik Monz, Bianca Moser (all Tax, Frankfurt), Dr. Jacob von Andreae (partner), Aylin Hoffs, Matthias Hahn (all Public Law, Düsseldorf), Dr. Alexander Molle (partner, IP/IT), Enno Burk (counsel, Pharmaceutical, both Berlin), Konrad Discher (counsel, Real Estate, Frankfurt), Mara Kerstan-Klie (Employment, Düsseldorf), Oliver Wolf (Corporate, Stuttgart).
Forward
